Respinova wins second Horizon 2020 Grant for top 1% of innovators. Read more here.

FDA Clears Pulsehaler for sale in the US. 

Read the press release here.

Breathe Well,             Live Well

CHRONIC OBSTRUCTIVE

  PULMONARY DISEASE (COPD)

Chronic Obstructive Pulmonary Disease (COPD) affects 5-14% of the world population over 40 years of age. Our mission is to reverse the suffering of COPD patients, and provide them with renewed quality of life and hope for the future.

Over 384M Patients
Direct Healthcare Costs of $30B in the USA and €50B in Europe
3rd Leading Cause of Death
PH Commercial New BU 4a.jpg
PH Logo.jpg
Pulsehaler is a novel treatment that uses Dynamic Air Pressure Pulses to facilitate the opening of airways and clearance of mucus.  
LEADERSHIP

Cliff Ansel, CEO

Medical Device Executive and Entrepreneur

Yuval Profile Pic_resize.jpg

Yuval Avni, CTO

Serial Entrepreneur, Inventor and Product Developer

Need more details? Contact us

We are here to assist. Contact us by phone, email or via our social media channels.